NHS Trust Adopts Technology

Deltex Medical Group PLC
14 April 2004


14 April 2004


                           Deltex Medical Group plc

      Medway NHS Trust adopts Deltex Medical's technology on a wide-scale

Deltex Medical Group plc ('Deltex Medical' / 'Company'), the AIM listed
haemodynamic monitoring company, today announces that Medway NHS Trust (the 
'Trust') has ordered sufficient quantities of CardioQ(TM) equipment to allow it 
to adopt haemodynamic optimisation as a standard of care for all its moderate 
and major risk surgical and critical care patients.

The Trust, which manages the Medway Maritime Hospital in Kent, has ordered ten
new CardioQ monitors for use in operating theatres and in critical care.  These
have been delivered to the hospital to allow the Trust to undertake a post
procurement audit, following which the Trust expects to be able to use the
CardioQ system to reduce average lengths of stay for its surgical patients.

In the event that the Trust's post procurement audit produces the positive
result that can be expected in light of previous experiences in other hospitals
in the UK, this will be the first Trust to fund the adoption of the CardioQ on a
wide scale entirely out of mainstream NHS operating cash flows without any
financial support from Deltex Medical for the data collection exercise.

The Board is also pleased to report that good progress continues to be made
towards successful conclusions in the data collection processes currently being
undertaken in ten hospitals across five other NHS Trusts.  In the sites where
these projects are most advanced, management information is becoming available
which supports the considerable anecdotal evidence from doctors that using the
CardioQ system more widely than before is having a positive impact on both the
quality and the efficiency of surgical patient care.  In the meantime, the
Company is working with a growing number of other hospitals to expand the use of
its technology to get more patients better, quicker.


Chief Executive, Andy Hill, commented:

'This new order is the most exciting indication yet that we are making
substantial progress towards establishing the CardioQ system as a standard of
care in the treatment of moderate and major risk surgical patients in the UK.'


For further information, please contact:-


Deltex Medical Group plc

Nigel Keen, Chairman               [e-mail]    01243 774 837

Andy Hill, Chief Executive         [e-mail]     01243 774 837

Ewan Phillips, Finance Director    [e-mail] 01243 774 837



Notes for Editors


Deltex Medical primarily develops, assembles and markets a cardiac function
monitor and therapy guidance device, the CardioQ ('CardioQ'/'Monitor'). The
CardioQ incorporates the Company's proprietary software and a small diameter,
easy-to-use, minimally invasive, disposable oesophageal probe that is used for
transmitting and receiving an ultra-sound signal. By using this technology, the
CardioQ provides clinicians with the ability to haemodynamically optimise
critically ill patients and those undergoing routine moderate to major surgery
through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.


There are already over 1,000 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 75 clinical publications on the use of the CardioQ
which have repeatedly:-

  • validated the results of the Monitor against known standards for measuring
    cardiac output, demonstrating that the technology works


  • proved that the CardioQ works in a wide range of surgical procedures



demonstrated that the Company's technology provides significant health and
economic benefits by helping to reduce post-operative complications and length
of hospital stays by an average of 30 to 40 per cent for a wide range of
patients.


                      This information is provided by RNS
            The company news service from the London Stock Exchange